Shanghai Junshi Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Shanghai Junshi Biosciences CEO'su Cong Li, Nov2021 tarihinde atandı, in görev süresi 7.92 yıldır. in toplam yıllık tazminatı CN¥ 4.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.013% ine doğrudan sahiptir ve bu hisseler HK$ 3.46M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 5.4 yıldır.

Anahtar bilgiler

Cong Li

İcra Kurulu Başkanı

CN¥4.2m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	3yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Oct 14

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Sep 30

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Aug 29

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Jun 28

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

May 06

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Mar 22

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Jan 26

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Dec 17

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Nov 20

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Sep 05

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

May 22

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

May 01

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Jan 16

Some Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 03

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Oct 12

CEO Tazminat Analizi

Cong Li'un ücretlendirmesi Shanghai Junshi Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-CN¥2b
Jun 30 2024	n/a	n/a	-CN¥2b
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥4m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥2b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥3b
Dec 31 2022	CN¥4m	CN¥4m	-CN¥2b

Tazminat ve Piyasa: Cong 'ın toplam tazminatı ($USD 583.12K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 515.61K ).

Tazminat ve Kazançlar: Cong şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Cong Li (60 yo)

3yrs

Görev süresi

CN¥4,224,000

Tazminat

Mr. Cong Li has been Co-Chief Executive Officer and Executive Director at Shanghai Junshi Biosciences Co., Ltd. since November 2, 2021 and served as Non-Executive Director since December 22, 2016 until Nov...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Xiong	Executive Chairman	9.7yrs	CN¥8.50m	13.09% HK$ 3.5b
Cong Li	Co-CEO & Executive Director	3yrs	CN¥4.22m	0.013% HK$ 3.5m
Jianjun Zou	GM, CEO & Executive Director	less than a year	CN¥5.86m	Veri yok
Ning Li	Executive Vice-Chairman of the Board	6.4yrs	CN¥9.93m	0.0051% HK$ 1.4m
Baohong Xu	Financial Director	4yrs	CN¥2.73m	0.00071% HK$ 190.6k
Zhuobing Zhang	Deputy GM & Executive Director	no data	CN¥8.13m	0.88% HK$ 235.7m
Sheng Yao	Senior VP & Executive Director	no data	CN¥8.01m	Veri yok
Gang Wang	Deputy GM	5.3yrs	CN¥1.32m	0.0010% HK$ 273.8k
Xin Li	Executive Director	less than a year	Veri yok	0.0096% HK$ 2.6m
Lu Yuan	Assistant to GM & Chief of Internal Audit Department	4yrs	Veri yok	Veri yok
Qian Wei	Chief Commercial Officer	3.3yrs	Veri yok	Veri yok
Patricia Keegan	Chief Medical Officer	no data	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: 1877 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Xiong	Executive Chairman	9.7yrs	CN¥8.50m	13.09% HK$ 3.5b
Cong Li	Co-CEO & Executive Director	7.9yrs	CN¥4.22m	0.013% HK$ 3.5m
Jianjun Zou	GM, CEO & Executive Director	2.4yrs	CN¥5.86m	Veri yok
Ning Li	Executive Vice-Chairman of the Board	6.4yrs	CN¥9.93m	0.0051% HK$ 1.4m
Zhuobing Zhang	Deputy GM & Executive Director	7.9yrs	CN¥8.13m	0.88% HK$ 235.7m
Sheng Yao	Senior VP & Executive Director	7.9yrs	CN¥8.01m	Veri yok
Gang Wang	Deputy GM	1.1yrs	CN¥1.32m	0.0010% HK$ 273.8k
Xin Li	Executive Director	1.1yrs	Veri yok	0.0096% HK$ 2.6m
Yi Tang	Non-Executive Director	9.5yrs	Veri yok	0.74% HK$ 198.5m
Chun Zhang	Independent Non-Executive Director	4.4yrs	CN¥200.00k	Veri yok
Xiaoyuan Feng	Independent Non-Executive Director	2.9yrs	CN¥200.00k	Veri yok
Hongyan Kuang	Chairman of the Board of Supervisors	less than a year	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1877 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Shanghai Junshi Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Recent updates

Third quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.42 loss in 3Q 2023)

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023)

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

New minor risk - Shareholder dilution

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)